The "canna-business" is booming, in case you haven't noticed. After generating a whopping $10.9 billion in legal sales last year in licensed stores, the newest "State of the Legal Cannabis Markets" report from the duo of Arcview Market Research and BDS Analytics projects that worldwide sales will top $40 billion by 2024, which is good enough for a more than 24% compound annual growth rate.

Beleave currently distributes recreational cannabis in three other Canadian provinces; British Columbia, Manitoba, and Ontario. The Company’s current portfolio of products includes mainstream and premium product offerings of pre-rolls, oils, and dried flower under both the Beleave and Seven Oaks brand names.

It’s no secret that cannabis plants offer various medical purposes. With the marijuana industry increasing as much as it has, there have been more treatment options surfacing, but adequate research is still lacking in some instances. As a result, cannabis stocks that focus the most on medical marijuana safety have been the ones gaining a competitive advantage in the market.

In this article, we’re going to look at three small-cap Canadian cannabis stocks that have a clinical trial advantage, choosing to focus on determining the medical benefits of cannabis rather than simply creating new products.

Truss CEO expects huge demand for cannabis-infused beverages in Canadian market 

June 27 marks the first-ever Post-traumatic stress disorder Awareness Day in the province of Ontario.

Post-traumatic stress disorder (PTSD) is a mental health condition that is catalyzed by a traumatic occurrence an individual has witnessed or experienced. The memories or impressions of these events can have a serious and long-lasting impact on an individual’s life.

The Capturing Eden Corporation, a unique line of stores offering medical cannabis assessments to underserviced areas in Ontario, is pleased to announce the opening of a new location in Owen Sound at 973 2nd Avenue West.

Stephen Barber, CEO of Capturing Eden Corp., said, “We decided to come to Owen Sound, as it is a greatly underserviced area that could be enhanced with proper medical cannabis assessments, as well as giving the opportunity for members of the community to purchase various hemp products.”

Shares in the world’s leading cannabidiol (CBD) brand Charlotte’s Web Holdings (TSX:CWEB) have gained more than 19% in fewer than the past two weeks of trading. Yet the company’s market capitalization, valued at under $800 million, suggests it’s still only a small-time player within the rapidly growing market for cannabis and cannabis-related products.

How big could this company get?

A $20 billion opportunity

In its most recent investor presentation, Canadian-licensed cannabis producer Aurora Cannabis suggested it thinks the potential size of the market for hemp and CBD products could reach as much as US$22 billion by the year 2022.

Canadians looking to enjoy soon-to-be-legalized pot-infused edibles could get hit with higher insurance premiums — depending on the size of their appetites.

Many insurers no longer treat cannabis users as cigarette smokers — who pay much higher premiums due to the high-risk activity — provided there is no tobacco or nicotine in products they use.

The shift came in recent years as Canada moved to legalize pot for recreational use, starting with dried flower, oils, plants and seeds.

However, to avoid paying more, cannabis usage must stay below a set number per week and many insurers count any kind of pot, whether it is smoked or sipped or chewed.

You likely don't need the reminder, but there aren't many industries expected to deliver a faster or more consistent growth rate over the next five to 10 years than legal marijuana. A newly released report from Arcview Market Research and BDS Analytics calls for more than $40 billion in global licensed-store salesby 2024, which is almost quadruple what was generated in 2018. Then, by the end of the next decade, cannabis cheerleader Cowen Group has called for $75 billion in annual worldwide sales.

But there's an even larger growth trend within the marijuana industry that has the full and undivided attention of Wall Street and investors. Namely, cannabidiol (CBD).

Marijuana edibles will soon be legal for purchase in Canada, but if you’re an experienced user, new regulations might mean that you need more than a single package to feel the desired effects.

“We think the regulations around edibles are going to be difficult to launch a product that consumers really want,” Anna Shlimak, head of investor relations and communications at Toronto-based cannabis company Cronos Group, told Investor’s Business Daily last week.